Yoshihito Kogure, M., Hiroya Hashimoto, P., Haruko Daga, M., Yasushi Fukuda, M., Akihiro Bessho, M., Tadaaki Yamada, M., . . . Masashi Kondo, M. Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50%. Elsevier.
Chicago Style (17th ed.) CitationYoshihito Kogure, MD, et al. Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50%. Elsevier.
MLA (9th ed.) CitationYoshihito Kogure, MD, et al. Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50%. Elsevier.
Warning: These citations may not always be 100% accurate.